Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
Jan 06, 2012
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection